Amoydx Genomics Equipment & Supplies In Nunavut

About 3-7%, 1%, 1%, 0.12%, 0.02%, 0.08% of NSCLC patients have gene fusions in ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes, and approximately 1% of lung adenocarcinoma patients harbor MET exon 14 skipping mutations. Targeted therapies have been developed and approved for use in patients whose tumors have some of the genomic alterations seen in NSCLC. For instance, there are ...

The phosphoinositide-3 -kinase catalytic alpha (PIK3CA) gene produces the p110 alpha (pl 10a) protein, which is one subunit of an enzyme called phosphatidylinositol 3-kinase (PI3K). PI3K plays a key role ofPI3K/Akt signaling pathway in numerous cellular processes critical for cancer progression, including metabolism, growth, survival, and motility. Somatic mutations in the PIK3CA gene are found ...

Lung cancer is one of the most common malignant tumor, and 80~85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC. The frequency of mutations in patients with NSCLC for the EGFR gene is 10~35%, for KRAS 15?25%, for BRAF1-4%, for NRAS is 1%, for HER2 2-4%, and for PIK3CA 1-3%. About 3-7% of NSCLC patients have gene fusion in ALK, 2% in ROS1, and 1% ...

The Homologous Recombination Repair (HRR) pathway plays an important role in double strand break, which is the major cause of cancer development. It has been demonstrated that loss of function of HRR genes (e.g. BRCA1, BRCA2, PALB2) and homologous recombination deficiency (HRD) will cause a higher risk of developing cancer, and patients with HRR gene mutations showed higher response to PARPi and ...